A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

NCT07043634 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioavailability Heathy Volunteers

Interventions

COMBINATION_PRODUCT: FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
COMBINATION_PRODUCT: FDC (24 mg ER torsemide and 30 mg Spironolactone) with food

Sponsor

Sarfez Pharmaceuticals, Inc.